Document is current
Any future updates will be listed below
-
Authors
Fitchett, David
Zinman, Bernard
Inzucchi, Silvio E.
Wanner, Christoph
Anker, Stefan D.
Pocock, Stuart
Mattheus, Michaela
Vedin, Ola
Lund, Søren S.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01131676 at ClinicalTrials.govDocuments that mention this clinical trial
Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
https://doi.org/10.2337/dc18-1355
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
https://doi.org/10.1681/asn.2018010103
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (Results)
https://doi.org/10.2337/dc17-1096
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial (Results)
https://doi.org/10.2337/dc20-1096
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories (Results)
https://doi.org/10.2215/cjn.14901219
Transforming the Care of Patients with Diabetic Kidney Disease
https://doi.org/10.2215/cjn.18641120
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Cardiovascular Effects of Noninsulin, Glucose-Lowering Agents: Need for More Outcomes Data
https://doi.org/10.1016/j.amjcard.2012.08.030
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
https://doi.org/10.1186/s12933-024-02328-6
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
https://doi.org/10.2337/dc18-1959
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance.
- License Information
-
More Information
Article History
Received: 7 March 2024
Accepted: 19 June 2024
First Online: 11 July 2024
Declarations
:
: The EMPA-REG OUTCOME trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines and was approved by local authorities. An independent ethics committee or institutional review board approved the clinical protocol at each participating center. All the patients provided written informed consent before study entry.
: Not applicable.
: Dr Fitchett has received financial support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck & Co., and Sanofi. Dr Zinman has received financial support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, and Sanofi. Dr Inzucchi has served as a consultant, speaker, or as a member of clinical trial steering committees for Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Merck/Pfizer, Lexicon, Bayer, vTv Therapeutics, Esperion and Abbott. Dr Wanner has received grants and served on steering committees for Boehringer Ingelheim; served on advisory boards for Boehringer Ingelheim, Merck Sharp & Dohme, and Bayer; and received lecture fees from Boehringer Ingelheim, Eli Lilly, AstraZeneca, Merck Sharp & Dohme, Mitsubishi, and Bayer. Dr Anker has received research support from Abbott Vascular and Vifor International, and personal fees from Boehringer Ingelheim, Bayer, AstraZeneca, Novartis, Vifor International, Impulse Dynamics, Respicardia, and St Jude Medical. Dr Pocock is a consultant for Boehringer Ingelheim. Dr Mattheus and Dr Lund are employees of Boehringer Ingelheim. Dr Vedin was an employee of Boehringer Ingelheim at the time of the study and is now an employee of AstraZeneca, Gothenburg, Sweden. Dr Lund owns shares in Novo Nordisk and shares in dynamically traded investment funds, which might own stocks from pharmaceutical companies.
